Antithrombin-III transfusion in disseminated intravascular coagulation

Area of Science:

• Hematology
• Coagulation Disorders
• Critical Care Medicine

Background:

• Disseminated intravascular coagulation (DIC) is a life-threatening condition characterized by abnormal activation of coagulation.
• Severe bleeding disorders pose significant challenges in clinical management, especially when combined with DIC.
• Antithrombin-III (AT-III) plays a crucial role in regulating coagulation.

Observation:

• Three patients presented with severe bleeding and concurrent DIC.
• Initial management strategies were considered.
• Treatment with human antithrombin-III concentrates was initiated.

Findings:

• The administration of human antithrombin-III concentrates led to effective control of bleeding and DIC.
• Subsequent administration of prothrombin complex and platelet suspensions further normalized haemostasis.
• Sustained normal haemostasis was achieved throughout clinical investigations and surgical procedures.

Implications:

• Human antithrombin-III concentrates represent a viable therapeutic option for severe bleeding disorders complicated by DIC.
• Combination therapy with prothrombin complex and platelets may be crucial for achieving and maintaining haemostasis.
• This approach offers a potential pathway to improved outcomes for critically ill patients with complex coagulation abnormalities.